A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes.
Kimya Hassani-ArdakaniaMark L LipmanDenny LaportaOriana Hoi Yun YuPublished in: Case reports in endocrinology (2019)
Physicians should inform patients to stop the use of SGLT-2 inhibitors when patients are unable to maintain hydration or during acute illness. Use of SGLT-2 inhibitors in managing type 2 diabetes should be done with caution among more vulnerable populations, including individuals with cognitive impairment and the elderly.
Keyphrases
- end stage renal disease
- type diabetes
- acute kidney injury
- cognitive impairment
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- metabolic syndrome
- cardiovascular disease
- insulin resistance
- patient reported outcomes
- liver failure
- intensive care unit
- weight loss
- skeletal muscle
- patient reported
- mechanical ventilation